Year Published
- 2008 (0)
- 2009 (0)
- 2010 (12) Apply 2010 filter
- (-) Remove 2011 filter 2011
- 2012 (6) Apply 2012 filter
- 2013 (1) Apply 2013 filter
- 2014 (0)
- 2015 (1) Apply 2015 filter
- 2016 (2) Apply 2016 filter
- (-) Remove 2017 filter 2017
- 2018 (1) Apply 2018 filter
- 2019 (1) Apply 2019 filter
- 2020 (0)
- 2021 (0)
Research Topics
Populations
Types of Research
Geography
- East Africa Region and Selected Countries (6) Apply East Africa Region and Selected Countries filter
- (-) Remove Global filter Global
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
- Southern Africa Region and Selected Countries (0)
- Sub-Saharan Africa (2) Apply Sub-Saharan Africa filter
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
Dataset
Current search
- (-) Remove West Africa Region and Selected Countries filter West Africa Region and Selected Countries
- (-) Remove Global & Regional Public Goods filter Global & Regional Public Goods
- (-) Remove South Asia Region and Selected Countries filter South Asia Region and Selected Countries
- (-) Remove Market & Value Chain Analysis filter Market & Value Chain Analysis
- (-) Remove Global filter Global
- (-) Remove 2011 filter 2011
- (-) Remove 2017 filter 2017
The share of private sector funding, relative to public sector funding, for drug, vaccine, and diagnostic research & development (R&D) differs considerably across diseases. Private sector investment in overall health R&D exceeds $150 billion annually, but is largely concentrated on non-communicable chronic diseases with only an estimated $5.9 billion focused on "global health", targeting diseases that primarily affect low and middle-income countries (LMICs). We examine the evidence for five specific disincentives to private sector global health R&D investment: scientific uncertainty, weak policy environments, limited revenues and market uncertainty, high fixed and sunk costs, and downstream rents from imperfect markets. Though all five may affect estimates of net returns from an investment decision, they are worth examining separately as each calls for a different intervention or remediation to change behavior.
An ongoing stream of EPAR research considers how public good characteristics of different types of research and development (R&D) and the motivations of different providers of R&D funding affect the relative advantages of alternative funding sources. For this project, we seek to summarize the key public good characteristics of R&D investment for agriculture in general and for different subsets of crops, and hypothesize how these characteristics might be expected to affect public, private, or philanthropic funders’ investment decisions.
The concept of global public goods represents a framework for organizing and financing international cooperation in global health research and development (R&D). Advances in scientific and clinical knowledge produced by biomedical R&D can be considered public goods insofar as they can be used repeatedly (non-rival consumption) and it is difficult or costly to exclude non-payers from gaining access (non-excludable). This paper considers the public good characteristics of biomedical R&D in global health and describes the theoretical and observed factors in the allocation R&D funding by public, private, and philanthropic sources.
This research brief synthesizes evidence on the effects of policy incentives on agricultural productivity. The evidence discussed is primarily drawn from documents provided to EPAR by the Bill and Melinda Gates Foundation. We review the role of policy and institutions in the Asian Green Revolution, a detailed case study on how policy changes have removed smallholder productivity constraints and contributed to growth, and the theory on the connection of policy incentives to productivity growth.